Navigation Links
Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix
Date:10/10/2009

PHOENIX and SAN CARLOS, Calif., Oct. 10 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) presented topline data today from its Phase 2 clinical trial of oral NKTR-118 at the American Academy of Pain Management's (AAPM) 20th Annual Clinical Meeting in Phoenix, Arizona. NKTR-118, an oral peripherally-acting opioid antagonist, is a late stage investigational product candidate in clinical development for the treatment of opioid-induced constipation. NKTR-118 was developed by Nektar, utilizing its proprietary small molecule advanced polymer conjugate technology platform.

Today's presentation at AAPM includes topline data previously announced by the company in March 2009. In a Phase 2 double-blind, randomized, placebo-controlled study of 208 patients with opioid-induced constipation, NKTR-118 met the primary endpoint of increase in spontaneous bowel movements over the baseline period. There was no reversal or reduction of opioid-mediated analgesia in any dose groups. NKTR-118 was also well tolerated with the most commonly reported side effects being dose-dependent gastrointestinal-related effects.

Download Today's Poster Presentation for NKTR-118

The poster presentation from today's AAPM 20th Annual Clinical Meeting can be found on Nektar's website at http://www.nektar.com/product_pipeline/cns_pain_oral_nktr-118and119.html

AAPM Poster #39: "NKTR-118 Significantly Reverses Opioid-Induced Constipation"

Complete Data from NKTR-118 Phase 2 Clinical Trial to be presented in Oral Plenary Session at ACG 2009

Data from the Phase 2 clinical trial of NKTR-118 have been accepted for presentation in an oral plenary session of the American College of Gastroenterology (ACG
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Topline Findings from Comparative Analysis of INVEGA(TM) and Quetiapine in Schizophrenia to be Postered at the 20th Annual U.S. Psychiatric and Mental Health Congress
2. HerbalScience Releases Results of Pilot Clinical Study on Efficacy of Its Proprietary Elderberry Extract in Addressing Flu-Like Symptoms
3. ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
4. Transdel Pharmaceuticals to Host Conference Call and Webcast on Tuesday, October 6, 2009 to Announce Top-Line Phase 3 Study Results for Lead Topical Pain Drug Ketotransdel(R)
5. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
6. Biotel Announces Fourth Quarter and Year End Results
7. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
8. BioMarin to Host Third Quarter 2009 Financial Results Conference Call and Webcast on Wednesday, October 28 at 5:00 p.m. ET
9. InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting
10. Encouraging HIV/AIDS Vaccine Trial Results Support GeoVax Labs, Inc. Strategy
11. Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015   GenoSpace , a ... interpretation and analysis of genomic and other biomedical ... has joined the company as Vice President of ... http://photos.prnewswire.com/prnh/20150730/250931 "GenoSpace partners with ... interpret, analyze and explore complex sets of genomic, ...
(Date:7/30/2015)... Dallas, Texas (PRWEB) , ... July 30, 2015 , ... ... professional and in-depth study on the current state of the global Propanol market with ... are Sinopec, CNPC, BASF, Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... of a field clinical study of its canine osteoarthritis stem cell product, currently ... Therapeutics (Kansas City, KS) and will be marketed in the US by Aratana. ...
(Date:7/30/2015)... , Inc. (NASDAQ: SNMX ), a leading company ... commercialize novel flavor ingredients for the food, beverage, and ... second quarter 2015. "Moving into the ... achieve our commercial and financial goals," stated John Poyhonen, ... our last quarterly earnings report, our two partners have ...
Breaking Biology Technology:GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9
... facility to support clinical development for ... lead drug candidate and other molecules, ... radiopharmaceutical company that designs, develops and,manufactures products to detect, ... completed commissioning its in-house manufacturing,capability to meet clinical trial ...
... (OTC Bulletin Board: YGYB) ("Yongye" or the "Company"),a leading ... in the People,s Republic of China, today announced its ... Second Quarter 2008 Highlights -- Revenue was ... quarter of 2007, and an ...
... 15 The backpack is a back-to-school,staple. In ... fashion accessory as,well. However, backpacks are a leading ... children and adolescents. As students head back to ... preventing,unnecessary backpack pain and injuries., The MCA ...
Cached Biology Technology:Cellectar, Inc. Begins GMP Production 2Yongye Biotechnology International Announces Second Quarter Results 2Yongye Biotechnology International Announces Second Quarter Results 3Yongye Biotechnology International Announces Second Quarter Results 4Yongye Biotechnology International Announces Second Quarter Results 5Yongye Biotechnology International Announces Second Quarter Results 6Yongye Biotechnology International Announces Second Quarter Results 7Yongye Biotechnology International Announces Second Quarter Results 8Yongye Biotechnology International Announces Second Quarter Results 9Yongye Biotechnology International Announces Second Quarter Results 10Yongye Biotechnology International Announces Second Quarter Results 11Minnesota Chiropractic Association Offers Backpack Safety Checklist 2
(Date:7/31/2015)... --NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market and creator of the Wocket® smart ... for ELECTRONIC CRYPTO-CURRENCY MANAGEMENT METHOD AND SYSTEM ... crypto-currencies such as Bitcoin into the consumer market of ... manage all payments.  The technology manages ...
(Date:7/27/2015)... LOS ANGELES , July 27, 2015 /PRNewswire/ ... providing evidence- and experience-based clinical improvement solutions, today ... coordination solution is now available on Android smartphones ... at inpatient and post-care organizations can use ZynxCarebook ... the same patient,s condition, streamline care transitions to ...
(Date:7/21/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market and ... it has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology ... but also the user using unique personal identifiers ...
Breaking Biology News(10 mins):NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4
... With climate change looming, the hunt for places that ... Obvious "sinks" for the greenhouse gas include the ... forests also play a role, and new research now suggests ... a study that drew on both historical and present-day datasets, ...
... 2009) The side effects of an experimental ... a variety of diseases are even more wide-ranging ... a University of Kentucky researcher. Following up on ... Nature, Dr. Jayakrishna Ambati, a UK ophthalmologist , ...
... Mathematical Morphology: Fundamentals and Applications (CRC Publisher, 2009), ... professor Frank Y. Shih http://web.njit.edu/shih offers ... and their relation to image processing. More than ... book places this knowledge into a theoretical framework. ...
Cached Biology News:Study reveals potential to amass more carbon in eastern North American forests 2Study reveals potential to amass more carbon in eastern North American forests 3Ambati study published in PNAS 2Ambati study published in PNAS 3Image processing and mathematical morphology in new text by NJIT professor 2